Kodiak Sciences Inc. (NASDAQ:KOD – Get Rating) – Capital One Financial upped their FY2026 EPS estimates for shares of Kodiak Sciences in a research note issued on Friday, May 19th. Capital One Financial analyst Z. Jallah now expects that the company will earn $1.28 per share for the year, up from their prior estimate of $1.17. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($4.98) per share. Capital One Financial also issued estimates for Kodiak Sciences’ FY2027 earnings at $4.74 EPS.
Separately, JPMorgan Chase & Co. reduced their target price on Kodiak Sciences from $12.00 to $10.00 and set a “neutral” rating on the stock in a report on Tuesday, April 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Kodiak Sciences presently has an average rating of “Hold” and an average price target of $12.86.
Kodiak Sciences Price Performance
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Braidwell LP purchased a new position in shares of Kodiak Sciences in the 4th quarter worth $6,546,000. BlackRock Inc. grew its position in Kodiak Sciences by 20.5% in the first quarter. BlackRock Inc. now owns 3,435,960 shares of the company’s stock worth $26,526,000 after acquiring an additional 584,762 shares in the last quarter. Bruce & Co. Inc. purchased a new position in Kodiak Sciences in the first quarter worth about $2,933,000. Krensavage Asset Management LLC purchased a new position in Kodiak Sciences in the first quarter worth about $2,849,000. Finally, Walleye Capital LLC grew its position in Kodiak Sciences by 1,904.5% in the first quarter. Walleye Capital LLC now owns 356,093 shares of the company’s stock worth $2,749,000 after acquiring an additional 338,328 shares in the last quarter. Institutional investors own 80.02% of the company’s stock.
About Kodiak Sciences
Kodiak Sciences, Inc is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD.
- Get a free copy of the StockNews.com research report on Kodiak Sciences (KOD)
- MarketBeat Week in Review – 5/15 – 5/19
- Applied Materials: Cracks In The Chip Recovery Or Time To Buy?
- Deere & Company Rallies On Farm Equipment Boom, Bullish Outlook
- How Many Roth IRAs Can You Have?
- Why You Should Consider Buying Nvidia Ahead Of Earnings
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.